Trial Profile

An Open-label Dose Escalation Study to Assess the Safety and Tolerability of IMM01-STEM in Participants With Muscle Atrophy Related to Knee Osteoarthritis

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 22 Nov 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs IMMUNA (Primary)
Indications Muscular atrophy; Sarcopenia
Focus Adverse reactions; First in man
Sponsors Immunis

Most Recent Events

19 Nov 2024 According to an Immunis media release, the team is currently analyzing the clinical datasets from the nine participants. A manuscript is in preparation detailing the results of the investigation, with a projected publication for early next year.
08 Nov 2024 Status changed from active, no longer recruiting to completed.
10 Sep 2024 Planned End Date changed from 20 Nov 2024 to 15 Jan 2025.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com